Circulating fibroblast growth factor 23 (FGF-23) is associated with adverse cardiovascular outcomes in CKD. Whether FGF-23 predicts cardiovascular mortality after kidney transplantation, independent of measures of mineral metabolism and cardiovascular risk factors, is unknown.
Introduction
Kidney transplantation is the treatment of choice for patients with ESRD. As a result of improved surgical techniques, immunosuppressive therapies, and prevention of opportunistic infections, the short-term prognosis of kidney transplant recipients in particular has improved dramatically over the past decades. However, the risk of premature death due to cardiovascular disease remains greatly increased in kidney transplant recipients compared with the general population (1) .
Deregulation of calcium/phosphate metabolism is common in CKD and in kidney transplant recipients with impaired renal function (2) . In patients with CKD, circulating levels of fibroblast growth factor 23 (FGF-23), parathyroid hormone (PTH), and phosphate have been identified as independent risk factors for cardiovascular disease and all-cause mortality (3) (4) (5) (6) (7) (8) (9) . Experimental studies demonstrated that FGF-23 may be directly involved in the development of left ventricular hypertrophy (LVH) (10) . Whether FGF-23 predicts cardiovascular mortality in renal transplant recipients is unknown.
Our primary hypothesis was that plasma FGF-23 is a risk factor for cardiovascular mortality in renal transplant recipients, independent of Framingham risk factors (recipient age and sex, systolic BP, antihypertensive treatment use, smoking status, diabetes mellitus, plasma total cholesterol, and HDL cholesterol), known determinants of FGF-23 (including estimated GFR [eGFR] and proteinuria (11) , and factors related to phosphate metabolism. We also addressed whether FGF-23 is associated with the left ventricular wall strain markers midregional fragment of pro-A-type natriuretic peptide (MR-proANP) and N-terminal-probrain natriuretic peptide (NT-proBNP), and with copeptin, the stable C-terminal portion of the precursor of vasopressin (12) , and whether these cardiac markers influence the association between FGF-23 and cardiovascular mortality.
Materials and Methods

Study Population
In this prospective cohort study, all renal transplant recipients with a graft functioning for at least 1 year who visited our outpatient clinic (University Medical Center Groningen, The Netherlands) between August 2001 and July 2003 were eligible to participate. This study was a post hoc analysis of a previously published study (13) ; plasma samples from 593 patients were available. All participants provided written informed consent. Patients were enrolled at median of 6.1 (interquartile range [IQR], 2.7-11.7) years after transplantation. Baseline visits were postponed if signs of infection were present. Patients diagnosed with cancer other than cured skin cancer were not eligible. A total of 606 patients signed written informed consent. The institutional review board approved the study protocol (METc 01/039), which was in adherence with the Declaration of Helsinki. The clinical and research activities being reported are consistent with the Principles of the Declaration of Istanbul as outlined in the Declaration of Istanbul on Organ Trafficking and Transplant Tourism.
Endpoints
The major outcome of the study was cardiovascular mortality. All-cause mortality and deathcensored graft failure were secondary outcomes. Adequate collection of up-to-date data on events and mortality was ensured by our continuous surveillance system; general practitioners or referring nephrologists were contacted in case the current status of a patient was unknown. Cause of death was obtained by linking the number of the death certificate to the primary cause of death as coded by a physician, according to the International Classification of Diseases, Ninth Revision (ICD-9). Cardiovascular death was defined as ICD-9 codes 410-447 (14) . Follow-up was completed until May 19, 2009 . There was no loss to follow-up.
Patient Characteristics and Laboratory Measurements
Relevant transplant characteristics were taken from a database containing information on all renal transplantations performed at our center since 1968. Standard immunosuppressive treatment are published previously (13) . Current medication, including active vitamin D use (alfacalcidol or calcitriol); presence of diabetes mellitus; and cardiovascular history were extracted from the medical record. Diabetes mellitus was defined according to the American Diabetes Association guidelines: fasting plasma glucose ≥126 mg/dl or use of antidiabetic medication (15) . Cardiovascular history was defines as a history of myocardial infarction, percutaneous transluminal angioplasty or stenting of coronary or peripheral arteries, bypass operation of coronary or peripheral arteries, intermittent claudication, amputation for vascular reasons, transient ischemic attack, or ischemic cerebrovascular accident. BP pressure was measured as described previously (13) . Smoking status was recorded with a self-report questionnaire.
Upon entry in the cohort (baseline), blood was drawn after an 8-to 12-hour overnight fasting period. EDTA plasma samples were stored at -80°C until assessment of biochemical parameters for this study. Plasma C-terminal FGF-23 levels were determined by sandwich ELISA (Immutopics, San Clemente, CA), with intra-assay and interassay coefficient of variation of <5% and <16%, respectively (16) . Plasma creatinine concentrations were determined using a modified version of the Jaffe method (MEGA AU 510, Merck Diagnostic, Darmstadt, Germany). PTH and 1,25(OH) 2 vitamin D were measured in EDTA plasma using radioimmunoassay, and 25(OH)-vitamin D levels were determined by isotope dilution-online solid phase extraction liquid chromatography-tandem mass spectrometry (17) . NT-proBNP levels were measured by immunoassay on an ELECSYS2010 instrument (ELECSYS proBNP, Roche Diagnostics, Germany). MR-proANP was measured with a sandwich immunoassay (MR-proANP LIA; B.R.A.H.M.S) (18) . Plasma copeptin was measured using a sandwich immunoassay (B.R.A.H.M.S GmbH/Thermo Fisher Scientific, Hennigsdorf/Berlin, Germany) (19) . Serum albumin, calcium, cholesterol, C-reactive protein, glucose, hemoglobin, and phosphate, and urinary phosphate, sodium, total protein, and urea were determined by routine laboratory measurements. we calculated eGFR using the CKD-Epidemiology Collaboration formula (20) .
Statistical analyses
Variable distribution was tested with histograms and probability plots. Normally distributed variables are presented as mean ± SD, and skewed variables as median (interquartile range). Baseline characteristics upon entry into the cohort were compared between tertiles of FGF-23 using one-way ANOVA, Kruskal-Wallis test, and chi-squared tests as appropriate. Skewed data were natural log-transformed for correlation analysis, Cox regression, and backward and forward linear analysis.
The associations between (log-transformed) FGF-23 levels and MR-proANP, NT-proBNP, and copeptin were assessed by Pearson correlation analysis. Backward linear regression was used to identify correlates of plasma FGF-23 levels. The following covariates were tested: age, sex, donor type (deceased or living), history of one or more acute rejection episodes, cold ischemia time, waist circumference, cardiovascular history, Framingham risk score factors, eGFR, proteinuria, serum phosphate, 24-hour urinary phosphate excretion (representing phosphate intake), 24-hour urinary urea excretion (representing protein intake (21)), plasma 25(OH)-vitamin D, 1,25(OH) 2 vitamin D, PTH, C-reactive protein, albumin, hemoglobin, MR-proANP, NT-proBNP and copeptin levels, use of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker (given potential interactions between the renin-angiotensin-aldosterone system and FGF-23 (22) ), use of active vitamin D, and number of antihypertensive drugs. Variables significantly associated with FGF-23 levels using backward linear regression analysis were subsequently tested in a forward linear regression model. Variables that were significant in this model were considered independent correlates of FGF-23 levels.
Risk ratios and conditional maximum likelihood estimates of the rate ratio for cardiovascular and all-cause mortality and graft failure were calculated per tertile of FGF-23. Confidence intervals were calculated using the Fisher Exact test. To further analyze the association between FGF-23 and outcomes, tertiles of FGF-23 were plotted in Kaplan Meier curves with log rank test. Subsequently, multivariable Cox regression models were built to assess the association between FGF-23 and outcomes, adjusted for potential confounders. We tested for effect modifications by invoking multiplicative interaction terms. Sensitivity analyses were performed in a predefined subgroup of patients with an eGFR between 30 and 90 mL/min per 1.73m 2 (n=493).
To determine the goodness of fit of the predictive models, the Akaike Information Criterion (AIC) was used. AIC is a statistical estimate of the trade-off between the likelihood of a model against its complexity. A lower AIC value indicates a better model fit. Furthermore, discrimination, or the ability of the risk prediction models to distinguish those with an event (i.e., cardiovascular or all-cause mortality or graft failure) from those who do not, was evaluated with the Harrell C-index. The C-index is analogous to the area under the receiver operating characteristic curve, for which larger values indicate better discrimination.
We assessed net reclassification improvement (NRI) for predefined risk categories of cardiovascular and all-cause mortality (<5%, 5%-10%, and >10%), and calculated integrated discrimination improvement (IDI) (23) . The NRI provides reclassification tables constructed separately for study participants with and without events and quantifies the correct movement between categories: upwards for events and downwards for nonevents.
Proportionality assumptions were tested using Schoenfeld tests and log-minus-log survival plots. All statistical analyses were performed using SPSS software, version 16.0 for Windows (IBM, Armonk, NY); Stata/SE software, version11.0 for Windows (College Station, TX); and OpenEpi (openepi.com). P values <0.05 were considered to represent statistically significant differences.
Results
Patient Characteristics
Patient characteristics are summarized in Table 1 . Overall, FGF-23 levels were 140 [IQR, 95-219] RU/ml, and eGFR was 47 ± 16 ml/min per 1.73 m 2 . None of the patients used dietary phosphate binders. Patients in the highest tertile FGF-23 tertile were older; were more likely to have received a graft from a deceased donor, to have had an acute rejection episode and to be a smoker; had a longer cold ischemia time; had a higher waist circumference and systolic and diastolic BP; had worse renal function; had lower serum albumin, HDL cholesterol, 1,25(OH) 2 vitamin D, and hemoglobin; had higher serum phosphate, NT-proBNP, MR-proANP, copeptin, PTH, and CRP levels; and had more proteinuria.
FGF-23 is Independently Associated with Cardiac Markers
Plasma FGF-23 levels were associated with NT-proBNP (r 2 =0.12; P<0.001), MR-proANP (r 2 =0.18; P<0.001), and copeptin (r 2 =0.18; P<0.001) levels in univariate analysis ( Figure 1 ).
Using backward and forward multivariable linear regression models, we found that copeptin was strongly and independently associated with plasma FGF-23 levels ( Table 2 ). Other independent correlates of FGF-23 levels were eGFR, serum phosphate, hemoglobin, and donor type (living or 
Baseline Plasma FGF-23 and Outcomes
During a median follow-up of 7.0 (IQR, 6.2-7.5) years, 128 patients (22%) died, 66 (11%) of cardiovascular disease; 54 (9%) had graft failure. Kaplan-Meier survival plots demonstrated a higher risk of cardiovascular mortality, all-cause mortality, and graft failure per increasing tertile of plasma FGF-23 ( Figure 2 ). Values expressed with a plus/minus sign are the mean ± SD; values with parentheses are median and interquartile range. All variables were determined at enrollment except gender, race, cause of the original kidney disease, cold ischemia time, total warm ischemia time and total number of HLA mismatches, which were assessed at time of transplantation. FGF-23, fibroblast growth factor 23; NT-proBNP, N-terminal probrain natriuretic peptide; MR-proANP, mid-region pro-A-type natriuretic peptide; CKD-EPI, CKD-Epidemiology Collaboration; ACE, angiotensinconverting enzyme; ARB, angiotensin receptor blocker. Risk ratios for cardiovascular mortality, all-cause mortality, and graft failure were significantly increased in the highest FGF-23 tertile (Table 3 ). In Cox regression models, the highest tertile of FGF-23 was consistently associated with a higher risk of cardiovascular mortality after adjustment for Framingham risk factors, history of cardiovascular disease, measures of renal function, phosphate metabolism, and cardiac wall stress (Table 4 ). To assess whether the association between FGF-23 and cardiovascular mortality was influenced by other factors, interaction analyses were performed. We found no evidence for interaction in the association between FGF-23 and cardiovascular mortality by eGFR (P for interaction=0.51), proteinuria (P=0.62), 24-hour urinary phosphate excretion (P=0.50), fractional phosphate excretion (P=0.87), or any Framingham risk factor. In addition, no significant interaction by NT-proBNP (P for interaction=0.26), MR-proANP (P=0.32), or copeptin (P=0.19) was observed. NT-proBNP and MR-ANP but not copeptin were independently associated with cardiovascular mortality in the full model (data not shown). The final models provided the best fit (lowest AICs); all models displayed good discrimination as suggested by relatively high Harrell C-indices ( Higher FGF-23 levels were also associated with a higher risk of all-cause mortality, both when analyzed per tertile and as continuous variable (Table 4 ). Higher tertiles of FGF-23 were also associated with a higher risk of death-censored graft failure in crude analyses, but significance was lost after adjustment for eGFR and proteinuria (Table 4 ). There was no significant interaction between the risk of graft failure and cardiovascular mortality (P=0.38). 
NRI and IDI
The NRI was calculated to assess the putative clinical utility of FGF-23 as a marker of (cardiovascular) mortality in addition to Framingham risk factors. Reclassification improved mainly in the patients who survived, where adding FGF-23 to the model resulted in reclassification into a lower-risk category ( 
Discussion
This study identified high plasma FGF-23 levels as an independent risk factor for cardiovascular mortality in kidney transplant recipients. The association was consistent in regression models adjusted for renal function, measures of mineral metabolism, and cardiovascular risk factors. The significantly improved NRI suggests that FGF-23 levels may have an additional value to Framingham risk factors to predict the risk of cardiovascular mortality in renal transplant recipients.
Our findings are in line with previous data linking high FGF-23 levels with incident cardiovascular disease and mortality in the CKD population (3, 24, 25) , and with a higher risk of all-cause mortality after kidney transplantation (26) . Furthermore, FGF-23 levels have been associated with established cardiovascular risk factors and with a higher risk of cardiovascular events in the general population (27, 28) . Although patients in the highest FGF-23 tertile were characterized by an overall high cardiovascular risk profile, the associations between plasma FGF-23 and (cardiovascular and all-cause) mortality remained significant after adjusting for several major cardiovascular risk markers, including Framingham risk factors, suggesting that FGF-23 is a strong and independent risk marker. The potential clinical relevance of FGF-23 in addition to established risk markers is further supported by improved reclassification (NRI and IDI). Furthermore, FGF-23, but not serum phosphate, PTH or vitamin D, was independently associated with cardiovascular mortality (Figure 3 ), suggesting a specific role for FGF-23. The observed association between elevated FGF-23 levels and a higher cardiovascular risk initially positioned FGF-23 as a biomarker of phosphate toxicity. More recently, animal studies demonstrated that FGF-23 has 'off-target' effects, directly contributing to the development of LVH (10) . We found that FGF-23 was independently associated with MR-proANP and NT-proBNP, both markers of left ventricular wall strain, and with copeptin, a stable peptide derived from the vasopressin precursor (29) . All three cardiac markers are used as markers of heart failure (30) . Although these associations are in line with a potential role for FGF-23 in LVH, we could not demonstrate modulation of the association between FGF-23 and cardiovascular mortality by these cardiac markers. Furthermore, only a small amount of FGF-23 was explained by copeptin, MR-proANP and NT-proBNP (Figure 1 ), suggesting that FGF-23 is independently related to cardiovascular and all-cause mortality.
In a previous study, the association between FGF-23 and cardiovascular events was modified by sex (31) . We could not confirm this effect modulation, which could be explained by differences in renal function between the Heart and Soul study (eGFR, 71 ± 23 mL/min per 1.73 m 2 ) and our cohort (eGFR, 47±16 mL/min per 1.73 m 2 ).. Data from 24-hour urine collections allowed us to include phosphate intake (assessed by 24-hour urinary phosphate excretion) (32) and excretion (fractional phosphate excretion) in our analyses. Neither measure interacted with the association between FGF-23 levels and cardiovascular mortality.
FGF-23 was also associated with an increased risk of graft failure in univariate analysis, in line with a previous study (26) . However, the association was no longer significant after adjustment for eGFR and proteinuria in addition to known risk factors for graft failure (Table 3 ). We hypothesize that renal function after transplantation has a stronger effect on the risk of graft failure than on the risk of mortality (33, 34) .
Possible limitations of our study include its post hoc nature and the use of ICD-9 codes rather than an independent adjudication committee to define the endpoint cardiovascular mortality. Although we adjusted for several confounders, including measures of renal function, which appeared to be the most important determinant of FGF-23 levels, the possibility of residual confounding cannot be fully excluded because not all determinants of FGF-23 are currently known. The sensitivity analyses in patients with an eGFR of 30-90 mL/min per 1.73 m 2 reduces the risk of confounding by renal function The fact that diabetic and hypertensive nephropathy were under-represented in our cohort, and that our cohort consisted almost entirely of Caucasian patients, limits the generalizability of our study. Because FGF-23 was measured only at a single time point in this cohort, we could not perform a repeated-measures analysis. Prevalent cohorts such as this may suffer from survivorship biases; these generally lead to an underestimation of the actual hazard ratio (35) . Using a relatively large number of covariates in the final Cox regression model might result in overfitting the model; however, the stepwise Cox models and the low AIC in the final model suggest that overfitting was no issue in our analyses. Finally, we did not have extensive structural or functional cardiac data (e.g., from echocardiography) available to further explore the mechanisms behind the observed association between FGF-23 and cardiovascular mortality. Strong points of this study, on the other hand, are the use of 24-hour urine collections, which enabled us to adjust for proteinuria and phosphate excretion, the availability of multiple markers of cardiovascular risk, and the complete follow-up.
In conclusion, to our knowledge this is the first study to identify FGF-23 as an independent risk factor for cardiovascular mortality after kidney transplantation. Although it may be relevant to consider therapies reducing FGF-23 levels (36) to improve cardiovascular outcomes, it should be kept in mind that high FGF-23 levels may serve an important physiological goal, namely to keep phosphate balance. A recent study demonstrated that specific FGF-23 blockade with a neutralizing antibody did reduce secondary hyperparathyroidism but increased serum phosphate, aortic calcification and mortality (37) . Whether specific reduction of FGF-23 or rather reducing phosphate load may improve cardiovascular prognosis after kidney transplantation should be addressed in future prospective studies.
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